¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2019³â ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ Ãá°èÇмú´ëȸ : 2019-03-22

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
2019³â ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ Ãá°èÇмú´ëȸ : 2019-03-22
±³À°ÀÏÀÚ : 2019-03-22
±³À°Àå¼Ò : ¹Ð·¹´Ï¾ö ¼­¿ï ÈúÆ°È£ÅÚ ÁöÇÏ 1Ãþ ±×·£µåº¼·ë  
±³À°ÁÖÁ¦ : 2019³â ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ Ãá°èÇмú´ëȸ
ÁÖÃÖ±â°ü : ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ
´ã´çÀÚ : À̼¼Àº
¿¬¶ôó : 02-784-2742  
À̸ÞÀÏ : secretariat@kcnp.or.kr      
±³À°Á¾·ù : Á¤½Å°Ç°­ÀÇÇаú      
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 12 ½Ã°£ 20ºÐ  
¼¼ºÎ¼ö°­·á : 80,000¿ø      
ºñ°í »çÀüµî·Ïºñ Æò»ýȸ¿ø:¸éÁ¦/Á¤È¸¿ø:50,000/ºñȸ¿ø:60,000/ÁØȸ¿ø¹×±âŸ:30,000 ´çÀϵî·Ïºñ Æò»ýȸ¿ø:10,000/Á¤È¸¿ø:60,000/ºñȸ¿ø:80,000/ÁØȸ¿ø¹×±âŸ:40,000      
       
±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 09:30~10:30 Á¤½Å°Ç°­ÀÇÇаúÀÇ ¾ÈÀüÇÑ Áø·á ȯ°æÀ» À§ÇÑ Çö½ÇÀûÀÎ ´ëÃ¥  ÀÌ»ó¿­(¿ø±¤ÀÇ´ë) 
È޽Ġ03¿ù 22ÀÏ  10:30~10:50 È޽Ġ () 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 10:50~11:15 Brain energy metabolism and vulnerability to stress  °­¿ø¼·(°æÈñÀÇ´ë) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 11:15~11:40 Diet and physical activity impact on mood disorder  ±è¹ÎÇõ(¿¬¼¼¿øÁÖÀÇ´ë) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 11:40~12:00 Brain mechanism of environmental risk for schizophrenia  °­½ÃÇö(±¹¸³Á¤½Å°Ç°­¼¾ÅÍ) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëC 10:50~11:15 Overview of resistant schizophrenia  ÀÌÁß¼±(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëC 11:15~11:40 Pharmacological treatment for resistant schizophrenia  ±è¼º¿Ï(Àü³²ÀÇ´ë) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëC 11:40~12:00 Non-pharmacological treatment for resistant schizophrenia  ÀÌÁ¤¼®(±¹¹Î°Ç°­º¸ÇèÀϻ꺴¿ø) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 12:00~12:30 Treatment strategy for young patients  Á¤Á¾Çö(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 12:30~13:00 Treatment strategy for schizophrenic patients who are intolerable to initial treatment  ¹Ú¼º¿ë(°è¿äº´¿ø) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëC 12:00~13:00 Optimal treatment of Brintellix: Translating clinical data into practice  ÀÌÁ¤±¸(ÀÎÁ¦ÀÇ´ë) 
È޽Ġ03¿ù 22ÀÏ  13:00~13:20 È޽Ġ () 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 13:20~13:45 Brexanolone iv for postpartum depression  ¿ì¿µ¼·(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 13:45~14:10 Esketamine nasal spray for depression  Á¤Çö°­(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 14:10~14:30 MDMA and ketamine assisted psychotherapy for PTSD  ¹ÚÁÖ¾ð(°è¿äº´¿ø) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëC 13:20~13:45 Overview of resistant bipolar disorder  ÀÓÀº¼º(½Å¼¼°èÈ¿º´¿ø) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëC 13:45~14:10 Pharmacological treatment for resistant bipolar disorder  ¼­Á¤¼®(°Ç±¹ÀÇ´ë) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëC 14:10~14:30 Non-pharmacological treatment for resistant bipolar disorder  ¹®Àº¼ö(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 14:30~14:55 Applying personalized medicine principles to cognitive remediation (CR) for schizophrenia spectrum disorders  ÀüÈ«ÁØ(°Ç±¹ÀÇ´ë) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 14:55~15:20 Predictors of lithium responses in bipolar disorder  ¹Ú¿µ¹Î(ÀÎÁ¦ÀÇ´ë) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 15:20~15:40 Neuropsychological and neuroimaging markers for recurrence of major depressive disorder  °­½Â°É(°¡ÃµÀÇ´ë) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëC 14:30~14:55 Overview of resistant depression  ±è¿ø(ÀÎÁ¦ÀÇ´ë) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëC 14:55~15:20 Pharmacological treatment for resistant depression  ¾çÁ¾Ã¶(ÀüºÏÀÇ´ë) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëC 15:20~15:40 Non-pharmacological treatment for resistant depression  ÀÌ°­¼ö(Â÷ÀÇ°úÇдë) 
È޽Ġ03¿ù 22ÀÏ  15:40~15:50 È޽Ġ () 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 15:50~16:15 Etiologic controversies in adult ADHD  ¼ºÇü¸ð(Â÷ÀÇ°úÇдë) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 16:15~16:40 Diagnostic controversies in adult ADHD  ½É¼¼ÈÆ(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 16:40~17:00 Treatment controversies in adult ADHD  È«Á¤¿Ï(Àͻ꺴¿ø) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëC 15:50~16:15 Overview of resistant OCD  ³ë´ë¿µ(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëC 16:15~16:40 Pharmacological treatment for resistant OCD  ÃµÀºÁø(¿µ³²ÀÇ´ë) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëC 16:40~17:00 Non-pharmacological treatment for resistant OCD  À̽ÂÀç(°æºÏÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2019³â ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ Ãá°èÇмú´ëȸ : 2019-03-22""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ¼¼ºê¶õ½ºº´¿ø ¾È°ú ±Ý¿äÁý´ãȸ(Applications of Biomaterials for Corneal Diseas) : 2019-03-22
´ÙÀ½±Û 2019³â Á¦1ȸ ÆÄÁÖ½ÃÀÇ»çȸ ¿¬¼ö±³À° : 2019-03-22
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20467 ¼­¿ï 2024 ´ëÇÑÇ÷¾×ÇÐȸ Á¶Á÷±¸Áõ½ÄÁõ¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-05-31 0 19 2024-04-17
20466 °æ±â ¾ÆÁִ뺴¿ø ÀÀ±ÞÀÇÇаú ¼³¸³ 30Áֳ⠱â³ä ½ÉÆ÷Áö¿ò : 2024-05-30 0 6 2024-04-17
20465 ¼­¿ï Á¦20Â÷ ´ëÇѸð¹ßÇÐȸ Çмú´ëȸ ÇÁ·Î±×·¥ : 2024-05-26 0 15 2024-04-17
20464 °æ±â 2024³â Á¦86Â÷ ´ëÇÑ»ý½ÄÀÇÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-26 0 8 2024-04-17
20463 ¼­¿ï 2024³â ´ëÇѼҾƼÒÈ­±â¿µ¾çÇÐȸ Ãá°è ½ÉÆ÷Áö¾ö : 2024-05-26 0 6 2024-04-17
20462 ¼­¿ï ´ëÇÑÃæ°ÝÆÄÄ¡·áÇÐȸ 2024 Ãá°è Çмú´ëȸ : 2024-05-26 0 10 2024-04-17
20461 ¼­¿ï Áø´Ü ü°èÀû¹®Çå°íÂû ¿öÅ©¼¥ : 2024-05-25 0 12 2024-04-17
20460 ¼­¿ï ´ëÇѺñ¸¸ÇÐȸ Á¦17ȸ ODOT (One Day Course of Obesity Treatment) : 2024-05-25 0 9 2024-04-17
20459 ¼­¿ï 2024³â Á¾¾ç¸é¿ª´ÙÇÐÁ¦¿¬±¸È¸ Ãá°è½ÉÆ÷Áö¾ö : 2024-05-24 0 5 2024-04-17
20458 ¼­¿ï 2024 Á¦12ȸ ´ëÇÑÇ÷¾×ÇÐȸ Ç÷¿ìº´¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-05-24 0 9 2024-04-17
20457 ¼­¿ï 2024³â ¿µµîÆ÷±¸ÀÇ»çȸ Ãá°è Çмú´ëȸ : 2024-05-21 0 9 2024-04-17
20456 ¼­¿ï 2024³â ´ëÇÑÀÓ»ó°Ç°­ÁõÁøÇÐȸ Ãá°èÇмú´ëȸ ¹× ¿¬¼ö°­Á : 2024-05-19 0 11 2024-04-17
20455 ¼­¿ï Á¦7Â÷ ´ëÇѼö¸éÈ£ÈíÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-19 0 4 2024-04-17
20454 ¼­¿ï 2024 ´ëÇѼҾÆÇ÷¾×Á¾¾çÇÐȸ Ãá°è¿¬¼ö°­Á : 2024-05-18 0 6 2024-04-17
20453 ¼­¿ï 2024³â ´ëÇÑ¿¬ÇÏÀå¾ÖÇÐȸ Á¦14ȸ Ãá°èÇмú´ëȸ : 2024-05-18 0 6 2024-04-17
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷